Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-naïve pre-diabetic and diabetic patients: A randomized controlled study

Bulatova, Nailya; Kasabri, Violet; Qotineh, Amenah; AL-Athami, Taiba; Yousef, Al-Motassem; AbuRuz, Salah; Momani, Munther; Zayed, Aymen

doi:10.1016/j.dsx.2017.11.003

Cited by 8 publications

(17 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors may interfere with the results. Blinding of participants and personnel was not mentioned in the six studies 18,21,25,35,37,38 (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effects of metformin in obesity treatment in different populations: a meta-analysis

Shi

Gan

et al. 2020

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Objective: Some studies have shown that metformin can reduce body weight. However, metformin has not been officially approved as a medicine for weight loss because its effect on different populations remains inconsistent. This meta-analysis aimed to summarize the weight loss effect of metformin quantitatively. Method: The randomized controlled and high-quality case-control trials of metformin monotherapy in obesity treatment were eligible. Baseline body mass index (BMI) was chosen as a self-control to compare the changes in BMI of different populations before and after treatment. All changes were calculated as differences between the final and initial BMI values (with negative values indicating a decrease). Results were presented as weighted mean difference (WMD) with a 95% confidence interval (CI 95%). Subgroup analysis was performed based on baseline BMI, age, daily dose, and duration of medication. Results: A total of 21 trials ( n = 1004) were included, and the meta-analysis of metformin treatment in different populations showed that metformin has a modest reduction in the BMI of included participants (WMD −0.98; 95% CI, −1.25 to −0.72), and the reduction of BMI was most significant in the simple obesity population (WMD −1.31; 95% CI, −2.07 to −0.54). The subgroup analysis showed that metformin treatment significantly reduced BMI in obesity patients with a BMI >35kg/m2 (WMD −1.12; 95% CI, −1.84 to −0.39) compared with before treatment. BMI in the high dose group decreased by 1.01 units (WMD−1.01; 95% CI, −1.29 to −0.73) and BMI did not continue to decrease significantly after treatment of more than 6 months. Conclusion: Patients treated with metformin experienced about a one-unit reduction in BMI at the end of treatment. But whether this decreased value produced enough weight loss (5% of baseline body weight) to qualify as a “weight loss drug” as current guidelines require, requires larger specific randomized control trials.

show abstract

“…These factors may interfere with the results. Blinding of participants and personnel was not mentioned in the six studies 18,21,25,35,37,38 (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

“…No study was considered low quality. Bulatova 37 found more than one generic metformin prescription to patients and possible variations in efficacy between generics. Cheang showed that no randomized control group has been designed in a long-term retrospective study.…”

Section: Risk Of Bias Assessmentmentioning

confidence: 99%

Effects of metformin in obesity treatment in different populations: a meta-analysis

Shi

Gan

et al. 2020

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…Atherosclerosis in type 2 diabetes is an inflammatory process characterised by systemic oxidative stress [86]. Randomised trials have reported reductions in markers of systemic oxidative stress in metformintreated type 2 diabetes patients [87][88][89][90][91][92][93]. Metformin has been shown to Finally, the gut microbiome is a powerful, if incompletely understood, modulator of health and disease, including diabetes and prediabetes (reviewed elsewhere [102,103]).…”

Section: Mechanisms Of Potential Relevance To Atherosclerotic Cardiov...mentioning

confidence: 99%

Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure

2022

View full text Add to dashboard Cite

“…A total of 21 studies were from Western Europe, 25,27,41,54,61,62,65,72,81,82,84 11 from North America, 25,27,41,54,61,62,65,72,81,82,84 9 from East Asia, 29,38,39,44,51,52,60,66,68 5 from South America, 28,69,78,79,83 5 from Western Asia, 28,69,78,79,83 and 3 each from Africa, 35,50,76 the Pacific, 26,42,75 and Eastern Europe. 45,74,80 A total of 90% of the studies were in populations with metabolic disease or conditions associated with metabolic disease: obesity, 25,32-34,37,41,43,45,47-49,52,57-60,62-64,67-74,76,77,79-83 diabetes or prediabetes, 26,32,38,46,59 hypertension, 40 coronary artery disease, 65 dyslipidemia,...…”

Section: Quantity Of Research Availablementioning

confidence: 99%

Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation

et al. 2021

View full text Add to dashboard Cite

show abstract

Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-naïve pre-diabetic and diabetic patients: A randomized controlled study

Cited by 8 publications

References 44 publications

Effects of metformin in obesity treatment in different populations: a meta-analysis

Effects of metformin in obesity treatment in different populations: a meta-analysis

Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure

Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation

Contact Info

Product

Resources

About